Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep

The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

The US Food and Drug Administration’s approvals of Genentech, Inc.’s Evrysdi (risdiplam) and MorphoSys AG’s Monjuvi (tafasitamab-cxix) ahead of their user goal dates helped bring the past week’s novel approval count to four – and the Center for Drug Evaluation and Research’s new molecular entity and novel biologic count for 2020 to 33.

Monjuvi’s approval was followed a few days later by the clearance of another biologic for hematologic oncology, GlaxoSmithKline plc’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers